Conference Coverage

ASH 2022: New clinical data challenge long-held assumptions


 

FROM ASH 2022

Inherited thrombophilia and miscarriage

Cynthia E. Dunbar, MD, chief of the translational stem cell biology branch at the National Heart, Lung, and Blood Institute in Bethesda, Md., who also spoke at the briefing, said that one of the abstracts most important to her practice is a study concerning pregnancy. It showed that low-molecular-weight heparin did not prevent miscarriage in pregnant women with confirmed inherited thrombophilia who had two or more prior pregnancy losses, compared with standard surveillance (Abstract LBA-5).

“This is not my field at all; on the other hand, as a hematologist and a woman, that’s what my emails in the middle of the night and my panicked phone calls are often about. Once somebody has one miscarriage, especially if they feel like they’re already over 30 and the clock is ticking, there’s a huge emphasis and a huge amount of pressure on obstetricians to basically work up for everything, kind of a shotgun [approach],” she said.

Those workups may reveal genetic mutations that are associated with mild elevations in risk for clotting. As a result, some pregnant women are put on anticoagulation therapy, which can cause complications for both pregnancy and delivery. These study findings don’t solve the problem of spontaneous pregnancy loss, but they at least rule out inherited thrombophilia as a preventable cause of miscarriages, Dr. Dunbar said.

Another potentially practice-changing abstract is a study showing that, in younger adults with mantle cell lymphoma, the addition of the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) to induction therapy and as maintenance with or without autologous stem cell transplant had strong efficacy and acceptable toxicity (Abstract 1).

“The results show that the ibrutinib-containing regimen without transplant is at least as good as the current standard of care with transplant.” Dr. Winter said. “Additional follow-up will be required to show definitively that an autotransplant is unnecessary if ibrutinib is included in this treatment regimen.”

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Chronic stress, especially race related, may hasten cancer death
MDedge Hematology and Oncology
Is there a doctor on the plane? Tips for providing in-flight assistance
MDedge Hematology and Oncology
Fungi inside cancer cells: ‘A new and emerging hallmark’
MDedge Hematology and Oncology
Give bacterial diversity a chance: The antibiotic dichotomy
MDedge Hematology and Oncology
A plane crash interrupts a doctor’s vacation
MDedge Hematology and Oncology
More vaccinated people dying of COVID as fewer get booster shots
MDedge Hematology and Oncology
Looking for a healthy meat substitute? Consider the potato
MDedge Hematology and Oncology
Analysis of doctors’ EHR email finds infrequent but notable hostility
MDedge Hematology and Oncology
Pandemic caused treatment delay for half of patients with CTCL, study finds
MDedge Hematology and Oncology
Diagnosed too late
MDedge Hematology and Oncology